The firm is interested in investing in seed and early-stage therapeutics companies, and breakthrough sciences that are created to deliver new medicines that improve human health. MRL Ventures Fund is interested in investing during Series A through C rounds in companies such as Imgo BioSciences, Entrada Therapeutics, Rheostat Therapeutics, and Kymera Therapeutics.
Documentaries, videos and podcasts
- VisterraA company developing antibody-based biological medicines for kidney diseases and other chronic diseases. Visterra was acquired by Otsuka Pharmaceutical in 2018.
- LifeMine TherapeuticsA therapeutics company founded in 2016 working in drug discovery and development using fungi. LifeMine uses genomics approaches to search for biosynthetic genes in eukaryotic microbes for the discovery of naturally inspired drugs to treat previously untreatable and significant chronic diseases.
- Rheostat TherapeuticsRheostat, located at 300 Technology Square, in Cambridge, Massachusetts is a biotech company developing treatments for neurodegenerative diseases by targeting mitophagy and autophagy pathways.